Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-12-17-Speech-3-407"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20081217.24.3-407"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Question No 44 by Emmanouil Angelakas ()
Article 14 of the proposal for a directive on the application of patients’ rights in cross-border healthcare () refers to the recognition of prescriptions issued in another Member State. Bearing in mind that not all proprietary medicines are marketed in all Member States, that the same proprietary medicine may be sold with different packaging or content in different Member States, that in some Member States, proprietary medicines may be sold only under a brand name rather than their generic name, and that medicines mentioned in a prescription may be in a language unfamiliar to the doctor or pharmacist providing the healthcare, what is the Commission’s view as to whether a product prescribed in a prescription, but not marketed in a given Member State, can be replaced by another medicinal product (princeps or generic), bearing in mind that this practice is outlawed in some Member States?
Will it provide more detailed information on the provisions it intends to adopt (pursuant to Article 14(2)(a) and (b)) to ensure that the authenticity of prescriptions can be verified and the medicines prescribed correctly identified?"@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
"Subject: Pharmaceutical treatment - cross-border healthcare"1
|
Named graphs describing this resource:
The resource appears as object in 2 triples